C&G Editor in Chief, Erin Harris

  1. Target Selection Drives The Future Of CAR T Therapy In Solid Tumors 4/13/2026

    Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.

  2. Mitigating Challenges In Solid Tumor Delivery 4/3/2026

    CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.

  3. Ensuring Quality Of CGT Materials 3/24/2026

    Here's why strong material selection, risk-based controls, and early analytics are critical for successful CGT development.

  4. Building Harmonized Real‑World Data In Oncology 3/13/2026

    Experts at PMWC 2026 emphasized that regulatory‑grade real‑world data in oncology will require prospectively collected, harmonized datasets that integrate multimodal clinical information.

  5. The In Vivo Cell Therapy Shift On Display At PMWC 2026 3/10/2026

    At PMWC 2026 in Santa Clara, we saw how in vivo CAR T and MRD‑guided strategies could reshape cell therapy by moving curative intent earlier while balancing bold innovation with practical scalability.

  6. Inside SynaptixBio's Mission To Develop A Therapy For H-ABC 3/9/2026

    SynaptixBio's Dr. Dan Williams discusses the company’s effort to develop an antisense oligonucleotide therapy that silences the mutant TUBB4A gene in the ultra-rare leukodystrophy H-ABC, highlighting the scientific, regulatory, and funding challenges of advancing treatments for extremely small patient populations.

  7. Powering AI And Synthetic Biology In Therapy Design 2/27/2026

    AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.

  8. Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real 2/18/2026

    Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.

  9. Disciplined CGT Will Win On 2026 Regulatory Flexibility 1/29/2026

    Wilson Bryan, M.D., and Daniela Drago, Ph.D., RAC, joined our our first Cell & Gene Live of 2026 to unpack what a more mature era of regulatory oversight means for sponsors.

  10. ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026 1/12/2026

    ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.